Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765587 | 1.00 | BTN3A1 (0.47) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL15765579 | 0.92 | BTN3A1 (0.46) | BTN3A1LMNAPRTN3 | |
| SCHEMBL13652726 | 0.92 | BTN3A1 (0.46) | BTN3A1LMNAPRTN3 | |
| SCHEMBL18583602 | 0.89 | BTN3A1 (0.58) | BTN3A1LMNAMEN1KMT2AELANE | |
| SCHEMBL18067134 | 0.89 | BTN3A1 (0.58) | BTN3A1LMNAMEN1KMT2AELANE | |
| SCHEMBL13921731 | 0.89 | BTN3A1 (0.58) | BTN3A1LMNAMEN1KMT2AELANE | |
| SCHEMBL12746449 | 0.89 | BTN3A1 (0.58) | BTN3A1LMNAMEN1KMT2AELANE | |
| SCHEMBL16587342 | 0.85 | BTN3A1 (0.57) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL18256378 | 0.85 | BTN3A1 (0.57) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL21158058 | 0.85 | BTN3A1 (0.55) | BTN3A1LMNAPRTN3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196419-B2 | Processes and intermediates for preparing anti-HIV agents | SAMHD1, DHPS, LSS | BTN3A1 4464/4885LMNA 1511/4885PRTN3 1576/4885 |
| US-20180079773-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | BTN3A1 4464/4885LMNA 1511/4885PRTN3 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.